secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2021-08-09T23:59:59+00:00
Accession:  0001193125-21-240438
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q2 revenue $123.2M (+79%), net income $20.7M; new $200M credit facility
--------------------------------------------------------------------------------

- Net revenue $123.2M (+79% YoY); Advanced Wound Care $111.4M (+87%), Surgical & Sports Med $11.8M (+27%).
- Net income $20.7M ($0.15 diluted EPS) vs loss $5.2M; adjusted EBITDA $25.1M (20.4% of revenue).
- FY2021 revenue guidance raised to $456-472M (35-40% growth); GAAP net income and adjusted EBITDA positive.
- New $200M credit facility ($75M term loan + $125M revolver) with LIBOR-based pricing; prior facility terminated.
- Legacy stockholders agreed not to sell shares until March 1, 2022 unless via underwritten secondary offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312521240438/0001193125-21-240438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312521240438/d184440d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-240438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer